PRINCETON, N.J., Nov. 23, 2020 /PRNewswire-PRWeb/ -- Nanocan Therapeutics Corporation, an early stage biotechnology company based in Princeton, New Jersey, announced today that it has closed a $1.4 million funding round. This funding round was led by Nanocan's Founder and CEO, Eric Broyles, along with LifeForce Capital and Bearcat Investments, LLC. To date, over $7 million in research and development grant funding has been invested in Nanocan's proprietary cancer treatment technology.
Nanocan is developing cutting-edge technologies that will lead to major advances in cancer treatment. Their nanotechnology-based innovations will focus on therapeutic medicines to treat certain cancers and respiratory diseases where current interventions are insufficient.
"Our mission is to never leave cancer patients and their families without hope for improvement and to never let them hear the words 'there is nothing we can do'," said Eric Broyles, founder of Nanocan. "We envision providing treatment modalities in the U.S. and worldwide. Outside of the U.S., Nanocan will focus on underserved and developing countries, starting with markets in Africa."
Nanocan has partnerships with several leading academic research institutions to develop and commercialize therapies that may ultimately result in optimal standards of care and improvements in the quality of life for cancer patients.
About Nanocan Therapeutics Corporation
Nanocan Therapeutics Corporation is a Princeton, New Jersey based early stage biotechnology company that is developing proprietary technologies that will lead to major advances in cancer treatment. Nanocan is committed to making its disruptive innovations available to cancer patients in the U.S. and globally, including Low and Middle-Income Countries ("LMICs"), starting with countries in Africa. With novel therapeutics, Nanocan seeks to transform treatments for certain cancers.
Media Contact
Nanocan Therapeutics Corporation, Nanocan Therapeutics Corporation, +1 (609) 241-9010, [email protected]
SOURCE Nanocan Therapeutics Corporation
Share this article